Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

15.51
-0.2100-1.34%
Post-market: 15.560.0500+0.32%19:51 EDT
Volume:3.87M
Turnover:60.66M
Market Cap:12.03B
PE:-10.77
High:16.28
Open:15.73
Low:15.38
Close:15.72
52wk High:36.91
52wk Low:13.83
Shares:775.37M
Float Shares:129.00M
Volume Ratio:1.91
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4400
EPS(LYR):-1.4439
ROE:-206.10%
ROA:-115.28%
PB:18.25
PE(LYR):-10.74

Loading ...

Summit Therapeutics Inc - FDA Decision on Ivonescimab Expected by Q4 2026

THOMSON REUTERS
·
Jan 12

Summit Therapeutics Announces Submission of Biologics License Application (Bla) to U.S. FDA Seeking Approval for Ivonescimab in Combination With Chemotherapy in 2L+ Treatment of Patients With Egfrm Nsclc

THOMSON REUTERS
·
Jan 12

Summit Therapeutics Inc - Enters 2026 With $710 Mln in Cash

THOMSON REUTERS
·
Jan 12

Summit Therapeutics reports inducement grants under Nasdaq listing rule

TIPRANKS
·
Jan 12

Summit Therapeutics Grants Stock Options to Seventeen New Employees

Reuters
·
Jan 10

Summit Therapeutics to Present Corporate Update and Ivonescimab Progress at J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

£5 Billion Discounts Propel Market! UK's New Car Sales Rebound to 2 Million in 2025 as Chinese Brands Accelerate Rise

Stock News
·
Jan 06

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ivonescimab’s HARMONi-3 Phase 3 Spotlight - Learn Why

Simply Wall St.
·
Dec 22, 2025

Has Summit Therapeutics Run Too Far After Its Huge Multi Year Share Price Surge?

Simply Wall St.
·
Dec 10, 2025

Russell 2000 Hits Record Highs, Silver Rallies To $60: What's Moving Markets Tuesday?

Benzinga
·
Dec 10, 2025

Summit Therapeutics (SMMT) Is Up 6.1% After Cancer Drug Ivonescimab Tops Keytruda Trial Results - What's Changed

Simply Wall St.
·
Dec 09, 2025

Summit Therapeutics Grants Stock Options to New Employees

Reuters
·
Dec 06, 2025

Summit Therapeutics Currently Down Seven Days Straight, On Pace for Longest Losing Streak Since February 2023 -- Data Talk

Dow Jones
·
Nov 21, 2025

Summit Therapeutics Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Nov 19, 2025

Summit Therapeutics (SMMT): Evaluating Valuation After Promising HARMONi-A Phase III Survival Results

Simply Wall St.
·
Nov 10, 2025

Does Positive Lung Cancer Trial Data Change the Bull Case for Summit Therapeutics (SMMT)?

Simply Wall St.
·
Nov 09, 2025

Clear Street Remains a Buy on Summit Therapeutics (SMMT)

TIPRANKS
·
Nov 08, 2025

Akeso Inc. Wins China Approval for Ivonescimab in EGFR-Mutated NSCLC

Reuters
·
Nov 08, 2025

Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer

MT Newswires Live
·
Nov 07, 2025

Summit Therapeutics Reports Ivonescimab Plus Chemotherapy Improves Survival in EGFR-Mutated NSCLC Phase III Trial

Reuters
·
Nov 07, 2025